Patents Assigned to AmCyte, Inc.
  • Publication number: 20070072292
    Abstract: The invention relates to the discovery of a selective cell surface marker that permits the selection of a unique subset of pancreatic stem cells having a high propensity to differentiate into insulin-producing cells or into insulin-producing cell aggregates.
    Type: Application
    Filed: September 27, 2005
    Publication date: March 29, 2007
    Applicant: AmCyte, Inc.
    Inventors: Wen-Ghih Tsang, Yanping Wang, Jinghua Tang
  • Patent number: 7101546
    Abstract: This invention relates to the discovery that an intermediate, differentiated stage of pancreatic stem cells exist that can be matured in situ into a stable cell line that produces insulin in response to glucose. These cells are advantageous in that they are both expandable and stable in culture. This invention avoids the step of culturing the intermediate stage stem cells into later stage pancreatic cells.
    Type: Grant
    Filed: December 20, 2002
    Date of Patent: September 5, 2006
    Assignee: AmCyte, Inc.
    Inventors: Wen-Ghih Tsang, Tianli Zheng, Yanping Wang
  • Publication number: 20040141957
    Abstract: This invention relates to the discovery that an intermediate, differentiated stage of pancreatic stem cells exist that can be propagated in a stable manner in successive serial passaging while maintaining insulin production in response to glucose. These cells are advantageous in that they are both expandable and stable in culture and can driven to late stage development, i.e. prototype islet cells. This invention further provides for culturing techniques that select for these intermediate differentiated stage cells and selectively eliminates early or late stage pancreatic cells.
    Type: Application
    Filed: February 10, 2004
    Publication date: July 22, 2004
    Applicant: AmCyte, Inc.
    Inventors: Wen-Ghih Tsang, Tianli Zheng, Chang Jiang Huang
  • Patent number: 6759039
    Abstract: This invention relates to the discovery that an intermediate, differentiated stage of pancreatic stem cells exist that can be propagated in a stable manner in successive serial passaging while maintaining insulin production in response to glucose. These cells are advantageous in that they are both expandable and stable in culture and can driven to late stage development, i.e. prototype islet cells. This invention further provides for culturing techniques that select for these intermediate differentiated stage cells and selectively eliminates early or late stage pancreatic cells.
    Type: Grant
    Filed: June 29, 2001
    Date of Patent: July 6, 2004
    Assignee: AmCyte, Inc.
    Inventors: Wen-Ghih Tsang, Tianli Zheng, Chang Jiang Huang
  • Publication number: 20040115805
    Abstract: The invention relates to the discovery of a selective cell surface marker that permits the selection of a unique subset of pancreatic stems cells having a high propensity to differentiate into insulin producing cells or into insulin producing cell aggregates.
    Type: Application
    Filed: September 8, 2003
    Publication date: June 17, 2004
    Applicant: AmCyte Inc.
    Inventors: Wen-Ghih Tsang, Tianli Zheng, Wei Liu
  • Publication number: 20030170215
    Abstract: This invention relates to the discovery that an intermediate, differentiated stage of pancreatic stem cells exist that can be matured in situ into a stable cell line that produces insulin in response to glucose. These cells are advantageous in that they are both expandable and stable in culture. This invention avoids the step of culturing the intermediate stage stem cells into later stage pancreatic cells.
    Type: Application
    Filed: December 20, 2002
    Publication date: September 11, 2003
    Applicant: AmCyte, Inc.
    Inventors: Wen-Ghih Tsang, Tianli Zheng, Yanping Wang